These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38323279)

  • 1. Sorafenib plus memory like natural killer cell combination therapy in hepatocellular carcinoma.
    Eresen A; Pang Y; Zhang Z; Hou Q; Chen Z; Yu G; Wang Y; Yaghmai V; Zhang Z
    Am J Cancer Res; 2024; 14(1):344-354. PubMed ID: 38323279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib plus memory-like natural killer cell immunochemotherapy boosts treatment response in liver cancer.
    Eresen A; Zhang Z; Yu G; Hou Q; Chen Z; Yu Z; Yaghmai V; Zhang Z
    BMC Cancer; 2024 Sep; 24(1):1215. PubMed ID: 39350084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI radiomics to monitor therapeutic outcome of sorafenib plus IHA transcatheter NK cell combination therapy in hepatocellular carcinoma.
    Yu G; Zhang Z; Eresen A; Hou Q; Garcia EE; Yu Z; Abi-Jaoudeh N; Yaghmai V; Zhang Z
    J Transl Med; 2024 Jan; 22(1):76. PubMed ID: 38243292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI monitoring of combined therapy with transcatheter arterial delivery of NK cells and systemic administration of sorafenib for the treatment of HCC.
    Zhang Z; Yu G; Eresen A; Hou Q; Yaghmai V; Zhang Z
    Am J Cancer Res; 2024; 14(5):2216-2227. PubMed ID: 38859849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of NK-based immunotherapy and sorafenib against hepatocellular carcinoma.
    Yang J; Eresen A; Scotti A; Cai K; Zhang Z
    Am J Cancer Res; 2021; 11(2):337-349. PubMed ID: 33575075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
    Sprinzl MF; Reisinger F; Puschnik A; Ringelhan M; Ackermann K; Hartmann D; Schiemann M; Weinmann A; Galle PR; Schuchmann M; Friess H; Otto G; Heikenwalder M; Protzer U
    Hepatology; 2013 Jun; 57(6):2358-68. PubMed ID: 23424039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma.
    Hage C; Hoves S; Strauss L; Bissinger S; Prinz Y; Pöschinger T; Kiessling F; Ries CH
    Hepatology; 2019 Oct; 70(4):1280-1297. PubMed ID: 31002440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
    Shi L; Lin H; Li G; Jin RA; Xu J; Sun Y; Ma WL; Yeh S; Cai X; Chang C
    Mol Cancer Ther; 2016 Apr; 15(4):731-742. PubMed ID: 26939703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Kamiya T; Chang YH; Campana D
    Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
    Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
    J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. iRGD-modified memory-like NK cells exhibit potent responses to hepatocellular carcinoma.
    Dong Y; Huang Y; Zhang Z; Chen A; Li L; Tian M; Shen J; Shao J
    J Transl Med; 2023 Mar; 21(1):205. PubMed ID: 36932395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review.
    Hosseinzadeh F; Verdi J; Ai J; Hajighasemlou S; Seyhoun I; Parvizpour F; Hosseinzadeh F; Iranikhah A; Shirian S
    Cancer Cell Int; 2018; 18():133. PubMed ID: 30214375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma.
    Zhuang L; Fulton RJ; Rettman P; Sayan AE; Coad J; Al-Shamkhani A; Khakoo SI
    Hepatol Int; 2019 Jan; 13(1):75-83. PubMed ID: 30467624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing hepatocellular carcinoma stem markers and their corresponding susceptibility to NK-cell based immunotherapy.
    Chiang J; Chen PC; Pham J; Nguyen CQ; Kaur K; Raman SS; Jewett A
    Front Immunol; 2023; 14():1284669. PubMed ID: 37954598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokines impact natural killer cell phenotype and functionality against glioblastoma
    Sivonen M; Sirviö KA; Wojciechowski S; Kailaanmäki A; Kaipainen S; Bailey A; Villalba M; Kekarainen T
    Front Immunol; 2023; 14():1227064. PubMed ID: 37841273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
    Zhang QB; Sun HC; Zhang KZ; Jia QA; Bu Y; Wang M; Chai ZT; Zhang QB; Wang WQ; Kong LQ; Zhu XD; Lu L; Wu WZ; Wang L; Tang ZY
    PLoS One; 2013; 8(2):e55945. PubMed ID: 23409093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
    Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
    Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.
    Kaweme NM; Zhou F
    Front Immunol; 2021; 12():683381. PubMed ID: 34220833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous Immune Enhancement Therapy for Cancer - Our experience since 2004.
    Terunuma H
    J Stem Cells Regen Med; 2012; 8(3):205-6. PubMed ID: 24693200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.